Humacyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.515 USD | +18.89% | +41.11% | +129.05% |
10/05 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
28/03 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+129.05% | 653M | |
+27.82% | 48.16B | |
-0.71% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.93% | 25.59B | |
-22.77% | 18.96B | |
+8.14% | 12.92B | |
+30.08% | 12.03B | |
-2.15% | 11.77B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023